EUVIMEDScopri EUVIMED
Übersichtsarbeit

Mammalian target of rapamycin inhibitors: A new‐possible approach for in‐utero medication therapy

Shohra Qaderi, Ali Javinani, Yair J Blumenfeld iD, Eyal Krispin iD, Ramesha Papanna iD, Frank A Chervenak, Alireza A Shamshirsaz iD

Prenatal Diagnosis · 2024

DOI: 10.1002/pd.6492 ↗

At a glance

Übersichtsarbeit in Prenatal Diagnosis, 2024. Written by Shohra Qaderi and 6 co-authors. Institution: Maternal Fetal Care Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Tuberous Sclerosis, Rhabdomyoma. Cited 14 times so far (Crossref); 50 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The mammalian/mechanistic target of rapamycin (mTOR) is a protein kinase that plays a crucial role in regulating cellular growth, metabolism, and survival. Although there is no absolute contraindication for the use of mTOR inhibitors during pregnancy, the specific fetal effects remain unknown. Available data from the past 2 decades have examined the use of mTOR inhibitors during pregnancy in patients with solid organ transplantation, showing no clear link to fetal complications or structural abnormalities. Recently, a handful of case reports and series have described transplacental therapy of mTOR inhibitors to control symptomatic and complicated pathologies in the fetus. The effect of these agents includes a significant reduction in lesion size in the fetus and a reduced need for mechanical ventilation in neonates. In this context, we delve into the potential of mTOR inhibitors as in‐utero therapy for fetal abnormalities, with a primary focus on lymphatic malformation (LM) and cardiac rhabdomyoma (CR). While preliminary reports underscore the efficacy of mTOR inhibitors for the treatment of fetal CR and fetal brain lesions associated with tuberous sclerosis complex, chylothorax, and LMs, additional investigation and clinical trials are essential to comprehensively assess the safety and efficacy of these medications.

Subjects

MeSH terms (MEDLINE)

Tuberous SclerosisRhabdomyomaPregnancyInfant, NewbornFemaleHumansSirolimusMTOR InhibitorsTOR Serine-Threonine KinasesFetus

Substances

SirolimusMTOR InhibitorsTOR Serine-Threonine Kinases

Authors and institutions

  • Maternal Fetal Care Center, Division of Fetal Medicine and Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, California, USA.
  • Division of Fetal Intervention, Department of Obstetrics, Gynecology and Reproductive Sciences, McGovern Medical School at UT Health Houston, Houston, Texas, USA.
  • Department of Obstetrics and Gynecology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lenox Hill Hospital, New York, New York, USA.

ORCID profiles: Yair J Blumenfeld, Eyal Krispin, Ramesha Papanna, Alireza A Shamshirsaz

Cite

APA

Qaderi, S., Javinani, A., Blumenfeld, Y. J., Krispin, E., Papanna, R., Chervenak, F. A., & Shamshirsaz, A. A. (2024). Mammalian target of rapamycin inhibitors: A new‐possible approach for in‐utero medication therapy. Prenatal Diagnosis. https://doi.org/10.1002/pd.6492

Vancouver

Qaderi S, Javinani A, Blumenfeld YJ, Krispin E, Papanna R, Chervenak FA, et al. Mammalian target of rapamycin inhibitors: A new‐possible approach for in‐utero medication therapy. Prenatal Diagnosis. 2024. doi:10.1002/pd.6492

BibTeX
@article{Qaderi2024,
  author = {Qaderi, Shohra and Javinani, Ali and Blumenfeld, Yair J and Krispin, Eyal and Papanna, Ramesha and Chervenak, Frank A and Shamshirsaz, Alireza A},
  title = {Mammalian target of rapamycin inhibitors: A new‐possible approach for in‐utero medication therapy},
  journal = {Prenatal Diagnosis},
  year = {2024},
  doi = {10.1002/pd.6492}
}
Start for free →